Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic NSCLC with EGFR mutations
Measurable disease according to RECIST criteria
Adequate hematological, renal and liver function
You may not be if
Previous chemotherapy or therapy against EGFR for metastatic disease
Symptomatic cerebral metastases
Pre-existing disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis
History of another malignancy except for carcinoma in-situ of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis
Concomitant use of coumarins
Clareo Health | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
